Two analysts waxed bullish on the future of the company.The stock of commercial-stage biotech Travere Therapeutics (TVTX +13.91%) barreled into the late holiday period in style. On a pair of new analyst notes covering the company, investors piled into its shares to leave them with an almost 14% gain on Hump Day. Buyout potentialThe first of those two updates was authored by Jefferies's Maury Raycroft. He flagged five biotechs as being particularly juicy takeover candidates in 2026, and Travere made the list ...